We hypothesize that the VEGF-targeting antibody Bevacizumab labeled with the fluorophore IRDye800CW (Bevacizumab-800CW) accumulates in VEGF-A expressing cancer, enabling esophageal cancer visualization using a NIR minimally invasive intra-operative…
ID
Bron
Verkorte titel
Aandoening
Esophageal cancer
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
·Intra-operative accumulation of Bevacizumab-800CW in VEGF-A overexpressing tissue as detected with intraoperative fluorescence imaging
Achtergrond van het onderzoek
There is a need for better visualization of resection margins and detection of small tumor deposits during surgery for esophageal cancer. Optical molecular imaging of esophageal adenocarcinoma (EAC) associated biomarkers is a promising technique to accommodate this need. The biomarker Vascular Endothelial Growth Factor (VEGF-A) is overexpressed in esophageal adenocarcinoma and its lymph node metastases and has proven to be a suitable target for molecular imaging
Doel van het onderzoek
We hypothesize that the VEGF-targeting antibody Bevacizumab labeled with the fluorophore IRDye800CW (Bevacizumab-800CW) accumulates in VEGF-A expressing cancer, enabling esophageal cancer visualization using a NIR minimally invasive intra-operative camera system. In this pilot intervention study we will determine the optimal dosage of Bevacizumab-800CW (4.5, 10 or 25 mg) to detect esophageal cancer tissue intra-operatively.
Onderzoeksopzet
-
Onderzoeksproduct en/of interventie
Targeted fluorescence imaging
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
· Patients scheduled for minimally invasive esophagectomy
· Suspected lymph node metastases based on EUS, PET or CT
· WHO performance score 0-2
· Aged 18 years or older
· Providing informed consent
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
· Known pregnancy or breastfeeding
· Known allergic reaction to Bevacizumab or other monoclonal antibody therapies
· Other invasive malignancy
· Inadequately controlled hypertension
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL5969 |
| NTR-old | NTR6343 |
| CCMO | NL61189.042.18 |
| OMON | NL-OMON50437 |